AKL Research and Development
News
Dr Annalisa Jenkins and Lord Michael Grade as Advisors
AKL Research and Development (AKLRD), a company developing an investigational osteoarthritis (OA) medicine, announces the appointment of Dr Annalisa Jenkins and Lord Michael Grade as advisors. Dr Jenkins is former Head of Global Research & Development and Executive Vice President Global Development & Medical at Merck Serono. Lord Grade is former Chairman of the BBC. […]
Read More
More weight loss tied to less knee pain for obese people
A recent article from Reuters Health has highlighted research by the American College of Rheumatology whose researchers have determined that obese people with knee osteoarthritis, a painful joint disease, may find greater symptom relief when they lose larger amounts of weight than when they shed fewer pounds, a recent study suggests. The researchers examined data […]
Read More
Phase I Clinical Trial at the University of Liverpool
The Phase I Clinical Trial to test AKL’s lead anti-inflammatory clinical candidate, APPA, as a potential new treatment for osteoarthritis is underway at the University of Liverpool Clinical Trials Unit. The trial has been approved for NIHR support. Osteoarthritis (OA) is the most common type of arthritis in the UK, affecting more than eight million […]
Read More
MHRA Approval for Formal Human Trials to Start
The University of Liverpool, as Sponsor of APPA’s clinical program, has received clinical trial authorisation (CTA) from the MHRA (Medicines & Healthcare Products Regulatory Agency) to commence the Phase I clinical trial. The ongoing clinical program will test AKLRD’s lead candidate, APPA, as a potential new treatment for osteoarthritis. David Sharples, Chief Executive Officer at […]
Read More
Under-exploited plants offer untold economic promise
A recent article in Nature by Ameenah Gurib Fakim, President of Mauritius and former Professor of Organic Chemistry, about the abundance of commercially available drugs that have their origins in plants. “Artemisinin, ginkgolides, quinine, reserpine, scopolamine, paclitaxel. What do these molecules have in common? They are all extracted from plants and transformed into useful drugs, […]
Read More
AKLRD and APPA in the Press
Recently there have been various press reports on AKLRD’s collaboration with Liverpool University on the clinical development of APPA. There has been coverage in both industry and mainstream press with Prof Rob Moots and Prof Steven Edwards being quoted extensively. Pharma Times: Liverpool Uni leads clinical trial of promising osteoarthritis drug Drug Development […]
Read More